HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edgewell Seeks Dismissal Of Wet Ones ‘99.99%’ Germ-Kill Suit

Executive Summary

The US FDA has primary jurisdiction over labeling claims on OTC consumer antiseptic rubs, and state false advertising claims lodged by the plaintiff are preempted by federal law, Edgewell Personal Care argues in its motion to dismiss a proposed class action in California federal court regarding Wet Ones germ-killing claims.

You may also be interested in...



FDA Advises Caution, Consultation Before Using 99.99% Germ-Killing Claims On Sanitizers

Manufacturers considering use of the popular 99.99% germ-kill claim on hand sanitizer products should consult the Office of Compliance, said Division of Nonprescription Drug Products director Theresa Michele during a recent industry workshop. “Be very, very cautious about the claims you are making,” she said.

Vi-Jon Says Hand Sanitizer False Advertising Suit Glosses Over ‘Common Germs’ Disclosure

A class action complaint in California’s Southern District, challenging the hand sanitizer manufacturer’s 99.99% germ-kill claim, ignores the asterisk on products’ primary display panels that links to a disclosure on rear labels, “*Effective at eliminating 99.99% of many common harmful germs & bacteria," according to Vi-Jon's 27 August motion to dismiss.

Hand Sanitizer Class Actions Highlight Need For FDA Regulatory Update

A growing number of class action complainants allege that 99.99% germ-killing claims on hand sanitizers are false and misleading. The suits cite potentially dangerous microorganisms that, according to plaintiffs, are impervious to active ingredients used in the category, and argue that bacteria reductions do not necessarily translate to illness or infection prevention.

Related Content

Topics

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel